These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 665313

  • 21. Human factor IX inhibitors: immunochemical characteristics and treatment with activated concentrate.
    Giddings JC, Bloom AL, Kelly MA, Spratt HC.
    Clin Lab Haematol; 1983; 5(2):165-75. PubMed ID: 6603957
    [Abstract] [Full Text] [Related]

  • 22. [Importance of PPSB fraction in the treatment of hemophilia A with antibodies against factor VIII].
    Hrubisková K.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1980; 107(4):672-82. PubMed ID: 6162735
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E.
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Incidence of immune responses following 102 infusions of autoplex in 18 hemophilic patients with antibody to factor VIII.
    Laurian Y, Girma JP, Lambert T, Meyer D, Larrieu MJ.
    Blood; 1984 Feb; 63(2):457-62. PubMed ID: 6419798
    [Abstract] [Full Text] [Related]

  • 27. Effect of treatment with activated prothrombin complex concentrate (FEIBA) on factor VIII-antibody level.
    Lechner K, Nowotny C, Krinninger B, Zegner M, Deutsch E.
    Thromb Haemost; 1979 Feb 15; 40(3):478-85. PubMed ID: 425062
    [Abstract] [Full Text] [Related]

  • 28. [Improvement in anti-hemophilic preparations and its problems. 3. Treatment of hemophilia patients with inhibitors; induction of immune tolerance by a low or intermediate dose regimen].
    Iizuka A.
    Rinsho Ketsueki; 1988 May 15; 29(5):640-8. PubMed ID: 3145995
    [No Abstract] [Full Text] [Related]

  • 29. Contact activation and factor VII after the use of an activated prothrombin complex concentrate (FEIBA) in hemophiliacs with inhibitors.
    Mariani G, Bouma BN, Mazzucconi MG, Avvisati G, Di Nucci GD, Corrao D, Mandelli F.
    Thromb Res; 1983 Aug 01; 31(3):475-88. PubMed ID: 20218003
    [Abstract] [Full Text] [Related]

  • 30. FEIBA versus NovoSeven in hemophilia patients with inhibitors.
    Franchini M, Coppola A, Tagliaferri A, Lippi G.
    Semin Thromb Hemost; 2013 Oct 01; 39(7):772-8. PubMed ID: 24014071
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Correction of the haemostatic defect in haemophiliacs without apparent correction of the coagulation defect.
    Serneri GG, Gensini GF, Gensini RA.
    Haemostasis; 1974 Oct 01; 3(3):149-57. PubMed ID: 4461416
    [Abstract] [Full Text] [Related]

  • 33. Blood and neoplastic diseases. Haemophilia and related disorders.
    Rizza CR.
    Br Med J; 1974 Oct 05; 4(5935):36-8. PubMed ID: 4547674
    [No Abstract] [Full Text] [Related]

  • 34. Feasibility of using thrombin generation assay (TGA) for monitoring of haemostasis during supplementation therapy in haemophilic patients without inhibitors.
    Ay Y, Balkan C, Karapinar DY, Akin M, Bilenoğlu B, Kavakli K.
    Haemophilia; 2012 Nov 05; 18(6):911-6. PubMed ID: 22639879
    [Abstract] [Full Text] [Related]

  • 35. Laboratory and clinical evaluation of concentrates for treatment of haemophilia.
    Verstraete M, Vermylen J.
    Acta Clin Belg; 1975 Nov 05; 30(5):437-48. PubMed ID: 1221749
    [No Abstract] [Full Text] [Related]

  • 36. Prophylaxis in haemophilia with inhibitors: update from international experience.
    Carcao M, Lambert T.
    Haemophilia; 2010 Mar 05; 16 Suppl 2():16-23. PubMed ID: 20132334
    [Abstract] [Full Text] [Related]

  • 37. FEIBA: mode of action.
    Turecek PL, Váradi K, Gritsch H, Schwarz HP.
    Haemophilia; 2004 Sep 05; 10 Suppl 2():3-9. PubMed ID: 15385040
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Factor concentrate usage in persons with hemophilia in New York State.
    Linden JV, Kolakoski MH, Lima JE, Du P, Lipton RA.
    Transfusion; 2003 Apr 05; 43(4):470-5. PubMed ID: 12662279
    [Abstract] [Full Text] [Related]

  • 40. Use of prothrombin complex concentrates in hemophiliacs with inhibitors: clinical and laboratory studies.
    Buchanan GR, Kevy SV.
    Pediatrics; 1978 Nov 05; 62(5):767-74. PubMed ID: 724319
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.